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Chemotherapy for cancer patients with chronic renal failure, undergoing hemodialysis (HD), has not
been well established. A 78-year-old woman with chronic renal failure due to hypertensive nephropathy,
undergoing HD, was diagnosed with small-cell lung cancer (SCLC) with multiple-organ metastases. She
was treated with 4 cycles of carboplatin (CBDCA) and etoposide (ETP) chemotherapy and a partial
response was achieved. She remained progression-free for at least 12 months after the completion of
chemotherapy. Pharmacokinetic analysis (PK) revealed that both agents were rapidly eliminated by HD;
however, the remnant platinum remained longer in the plasma. Chemotherapy with CBDCA and ETP was
effective and could be safely administered to a patient with SCLC undergoing HD.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Lung cancer is a leading cause of cancer-related death in many
developed countries. Because small-cell lung cancer (SCLC) is one of
the most chemo-sensitive solid malignancies, chemotherapy is
administered in most cases; however, chemotherapy for patients
with chronic renal failure, undergoing hemodialysis (HD), has not
been well established. Here, we treated an SCLC patient, under-
going HD, with carboplatin (CBDCA) and etoposide (ETP), and
analyzed the pharmacokinetics (PK).2. Case report
A 78-year-old woman with chronic renal failure due to hyper-
tensive nephropathy, undergoing HD, presented with lymphade-
nopathy of the right hilum in January 2008. Histopathologic study
of transbronchial biopsy specimens revealed SCLC. She had
metastases in the liver, bone and right adrenal gland; therefore, she
was diagnosed with extensive disease (ED). She had been under-
going HD three times a week for the past 2 years. Her Eastern
Cooperative Oncology Group performance status was 1. Consid-
ering her good performance status and the high chemo-sensitive
nature of SCLC, we treated her with a combination of CBDCA and
ETP. The treatment schedule and dose of each agent were based on
a previous study.1 In the ﬁrst cycle, 300 mg/m2 CBDCA on day 1, and: þ81 75 751 4643.
).
rved.50 mg/m2 of ETP on days 1 and 3 were administered. Each agent
was diluted in 250 ml of 5% glucose solution and injected over
60 minutes. CBDCA was administered after the completion of ETP
administration on day 1. HD was started 1 h after administration of
the anticancer agent each day. Prophylactic administration of
granulocyte colony-stimulating factor (G-CSF) was not carried out.
She received 4 cycles of chemotherapy at 3–4week intervals. No
non-hematologic toxicities were observed, except for alopecia,
throughout the treatment. Hematologic toxicities, such as grade
3 neutropenia and grade 4 thrombocytopenia, were observed
during the ﬁrst cycle and each agent was reduced to 80% dose from
the second cycle. Platelets and red blood cells were transfused
during the ﬁrst and second cycles, respectively. G-CSF administra-
tion was not required. Table 1 shows the hematologic toxicities in
each cycle. After two cycles of treatment, she achieved a partial
response and has remained progression-free for at least 12 months
after the completion of chemotherapy (Fig. 1).
PK analysis was conducted for each agent. Blood samples were
collected 1, 2, 4, 6, 8, 24 h after the administration of each agent in
the ﬁrst cycle. For the analysis of CBDCA, blood samples were also
collected just before the administration of CBDCA in subsequent
cycles. Total platinum and ETP in the plasma were measured by
atomic absorption spectrometry and high-pressure liquid chro-
matography, respectively (Figs. 2 and 3).2,3 The PK pattern of each
agent was similar to the previous report of SCLC patients under-
going HD1,4 and of patients with normal renal function.5,6 The
serum CBDCA concentration rapidly decreased during the ﬁrst 24 h
by HD; however, the remnant platinum remained longer in the
plasma: 0.29 mg/ml at the beginning of the second cycle, 0.48 mg/ml
Table 1
Hematologic toxicities.
Cycle Dose (mg/m2) Neutrophils
(/mm3)
Hemoglobin (g/
dl)
Platelets
(104/mm3)
CBDCA ETP Before Nadir Before Nadir Before Nadir
1 300 50 5000 600 12.7 9.4 24.3 2.2
2 240 40 4800 1600 9.3 6.2 29.6 6.1
3 240 40 3300 1500 11.0 10.2 28.6 6.5
4 240 40 2500 1500 10.6 8.2 9.0 2.4
CBDCA, carboplatin; and ETP, etoposide.
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of the fourth cycle, respectively.
3. Discussion
Currently, it is not uncommon for patients undergoing HD to
suffer fromvarious types of cancer; however, the safety and efﬁcacy
of chemotherapy have not been well described in such patients. In
this paper, we reported a patient with small-cell lung cancer whoFig. 1. CT images before and after chemotherapy. Arrows indicat
0 5 10 25
2
4
6
8
10
12
14
Time (hours)
Pl
as
m
a 
pl
at
in
um
 
co
n
ce
n
tr
at
io
n 
(µ
g/m
l)
Fig. 2. Platinum concentration in plasma after the administration of carboplatin.was successfully treated with CBDCA and ETP combined with
hemodialysis. To our knowledge, this regimen, with the same
treatment schedule for patients with SCLC undergoing HD, has
been reported in 5 patients by 3 authors,1,4,7 and our report has
conﬁrmed the safety and efﬁcacy of this treatment strategy.
The PK pattern of each agent during the ﬁrst 24 h was almost
identical to previous reports.1,4 In this report, we measured the
serum CBDCA concentration also just before the second, third, and
fourth cycles, and found that it remained longer in the plasma. In
this patient, hematologic toxicities persisted even after the reduc-
tion of both agents from the second cycle. As Inoue et al. mentioned
remnant platinum could cause prolongedmyelosuppression. When
platinum agents are repeatedly administered in patients under-
going HD, more careful attention should be paid to toxicity.
In conclusion, we report a patient with SCLC, undergoing HD,
who was successfully treated with CBDCA and ETP. Combined with
the results of previous reports, this regimen can be recommendable
for such patients. Other regimens, such as cisplatin and ETP,8
CBDCA and irinotecan,9 and amrubicin,10 have also been reported to
be safe and effective in patients undergoing HD. Although furthere shrinkage of mediastinal lymphnode and liver metastasis.
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Fig. 3. Etoposide concentration in plasma after administration. Solid and dotted lines
indicate etoposide concentration on day 1 and day 3, respectively.
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withheld because of HD.
Conﬂict of interest statement
The authors have no conﬂicts of interest to declare.References
1. Inoue A, Saijo Y, Kikuchi T, Gomi K, Suzuki T,MaemondoM, et al. Pharmacokinetic
analysis of combination chemotherapy with carboplatin and etoposide in small-
cell lung cancer patients undergoing hemodialysis. Ann Oncol 2004;15(1):51–4.
2. LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, et al.
Analysis of platinum in biological materials by ﬂameless atomic absorption
spectrophotometry. Biochem Med 1977;18(2):184–91.
3. Allen LM. Analysis of 40-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-
beta-D-glucopyranoside) by high-pressure liquid chromatography. J Pharm Sci
1980;69(12):1440–1.4. Takezawa K, Okamoto I, Fukuoka M, Nakagawa K. Pharmacokinetic analysis of
carboplatin and etoposide in a small cell lung cancer patient undergoing
hemodialysis. J Thorac Oncol 2008;3(9):1073–5.
5. Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, et al. Clinical
pharmacokinetics of carboplatin. J Clin Pharmacol 1988;28(3):208–15.
6. D’Incalci M, Farina P, Sessa C, Mangioni C, Conter V, Masera G, et al. Pharma-
cokinetics of VP16-213 given by different administration methods. Cancer
Chemother Pharmacol 1982;7(2–3):141–5.
7. Haraguchi N, Satoh H, Ogawa R, Hashimoto Y, Sekizawa K. Chemotherapy in
a patient with small-cell lung cancer undergoing haemodialysis. Clin Oncol
(R Coll Radiol) 2005;17(8):663.
8. Watanabe R, Takiguchi Y, Moriya T, Oda S, Kurosu K, Tanabe N, et al. Feasibility
of combination chemotherapy with cisplatin and etoposide for haemodialysis
patients with lung cancer. Br J Cancer 2003;88(1):25–30.
9. Koshiishi H, Yasui T, Takahashi E, Kakimoto Y, Okamura T, Minami T, et al.
Carboplatin and CPT-11 chemotherapy in a hemodialysis patient with small-cell
lung cancer. Gan To Kagaku Ryoho 2007;34(12):2071–3.
10. Isogai S, Totani Y, Kohashi Y, Mieno Y, Imizu H, Yoneda Y, et al. A case of advanced
small cell lung cancer complicated by chronic renal failure treated with amru-
bicin. Gan To Kagaku Ryoho 2008;35(9):1591–3.
